Community Update on the positive decision by EMA regarding the high-dose regimen of nusinersen in the treatment of SMA.
Biogen announced that the high dose regimen of nusinersen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
This will now be reviewed by the European Commission, with a final decision on its approval expected in January 2026.